RIOK2 Modulation for Hematopoietic Differentiation Defects
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hematologic disorders such as anemia, myelodysplastic syndromes, and metabolic disorders are limited, and there is a need for effective druggable targets to address defects in blood cell differentiation and telomere shortening associated with aging and diseases like idiopathic pulmonary fibrosis.
Innovation Solution
Stabilizing and increasing the copy number, expression, and activity of RIOK2 in subjects to correct hematopoietic differentiation defects, or decreasing RIOK2 activity to treat polycythemia vera, using agents that specifically target RIOK2's copy number, expression, or activity, and assessing efficacy through monitoring changes in RIOK2 levels over time.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for hematologic disorders are used, then existing therapy options are maintained, but treatment effectiveness is limited due to lack of druggable targets
Solution Approach 1:
The patent introduces RIOK2 as an intermediary molecular target that mediates the treatment of hematologic disorders. By identifying RIOK2 as a specific protein target involved in hematopoietic differentiation, the invention provides a druggable intermediary between therapeutic agents and the underlying pathogenic mechanisms of disorders such as anemia and myelodysplastic syndromes
Solution Approach 2:
The patent applies parameter changes by modulating RIOK2 expression levels and activity states to treat different hematologic conditions. By altering the expression parameter of RIOK2 (increasing for anemia, decreasing for polycythemia vera), the invention creates versatile treatment approaches for multiple disorders through the same molecular target
2Reliability
If RIOK2 activity is increased to treat anemia and hematologic disorders, then differentiation defects are corrected, but RIOK2 activity must be precisely controlled to avoid adverse effects
Solution Approach 1:
The patent applies dynamics by enabling adjustable and reversible modulation of RIOK2 activity rather than fixed inhibition or activation. Through various therapeutic agents that can dynamically regulate RIOK2 expression and function, the treatment can be tuned to achieve optimal therapeutic effects while minimizing adverse effects, allowing flexible control during treatment
Solution Approach 2:
The patent incorporates feedback mechanisms through monitoring RIOK2 expression levels and hematologic parameters to guide treatment adjustment. By assessing patient response and RIOK2 activity states, therapeutic regimens can be optimized to maintain RIOK2 within therapeutic ranges, preventing both insufficient treatment and excessive activation
3Adaptability or versatility
If RIOK2 modulation is used to treat hematologic disorders, then new therapeutic opportunities are created, but treatment complexity increases due to need for precise RIOK2 level monitoring
Solution Approach 1:
The patent applies universality by using RIOK2 modulation as a multi-functional therapeutic platform that can treat diverse hematologic disorders including anemia, myelodysplastic syndromes, and polycythemia vera. The same molecular target and monitoring approach serve multiple therapeutic indications, reducing the need for disorder-specific complex assessment protocols
Data Source
AI summary
The present invention provides methods of treating a disease or disorder in a subject comprising administering to the subject a therapeutically effective amount of an agent that modulates RIOK2.